Review article: Current management of metastatic colorectal cancer - The evolving impact of targeted drug therapies

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 11, 2008, Pages 997-1005

  Yau, T ^a   Chan, P ^a   Ching Chan, Y ^a   Wong, B C Y ^a   Liang, R ^a   Epstein, R J ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; CETUXIMAB; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PTK 78; RALTITREXED; STEM CELL FACTOR; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UFT; VASCULOTROPIN; VASCULOTROPIN A; VATALANIB;

ADVANCED CANCER; ALGORITHM; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; HUMAN; LIVER METASTASIS; MEDLINE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 42949164905     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03684.x     Document Type: Review

References (75)

1. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005 6 : 871 6.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
3. Yiu HY, Whittermore AS, Shibata A. Increasing colorectal cancer incidence rate in Japan. Int J Cancer 2004 109 : 777 81.
4. Winawer SJ. Natural history of colorectal cancer. Am J Med 1999 106 : 3S 6S discussion 50S 51S.
5. Cho KR, Vogelstein B. Genetic alterations in the adenoma - carcinoma sequence. Cancer 1992 70 (6 Suppl. 1727 31.
6. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995 122 : 321 6.
7. Epstein RJ, Leung TW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 2007 13 : 11 7.
8. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989 63 (6 Suppl. 1026 30.
9. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003 361 : 368 73.
10. Herrmann R, Knuth A, Kleeberg U, et al. Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society. Ann Oncol 1992 3 : 539 43.
11. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989 7 : 1447 56.
12. O'Dwyer PJ, Manola J, Valone FH, et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 2001 19 : 2413 21.
13. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998 16 : 301 8.
14. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992 10 : 896 903.
15. Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 1998 16 : 3461 75.
16. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007 25 : 4217 23.
17. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004 126 : 394 401.
18. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer [see comment]. N Engl J Med 2003 349 : 247 57.
19. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 355 : 1041 7.
20. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000 343 : 905 14.
21. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007 25 : 4779 86.
22. de Gramont A, Louvet C, Andre T, et al. Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'etude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD). Rev Med Interne 1997 18 (Suppl. 4 372s 8s.
23. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004 22 : 23 30.
24. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004 22 : 229 37.
25. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004 22 : 1209 14.
26. Damianovich D, Adena M, Tebbutt NC. Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. Br J Cancer 2007 96 : 546 50.
27. Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003 64 : 131 8.
28. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 285 : 1182 6.
29. Van Cutsem E, Michael M, Berry S, et al. Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: First BEATrial. In : 2007 Gastrointestinal Cancers Symposium, Orlando J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Ed.) 25 : 4072.
30. Grothey AMS, Hedrick E, Purdie D, Yi J, Dong W, Kozloff M, and the BRiTE Study Investigators. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). In : ASCO Annual Meeting 2007, Chicago J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Ed.) 25 : 4036.
31. Gruenberger T, Gruenberger B, Scheithauer W. Neoadjuvant therapy with bevacizumab. J Clin Oncol 2006 24 : 2592 3 author 2593 4.
32. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 21 : 60 5.
33. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005 23 : 3697 705.
34. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005 23 : 3706 12.
35. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 42.
36. Hochster HSLLH, Ramanathan RK, Hainsworth JD, et al. Results of the TREE-2 cohort: Safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer. In : 2006 Gastrointestinal Cancers Symposium, 2006 (abstract 244).
37. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 25 : 1539 44.
38. Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007 26 : 443 52.
39. NCCN Clinical Practice Guidelines in Oncology 2007. http://www.nccn.org.
40. Karameris A, Kanavaros P, Aninos D, et al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol Res Pract 1993 189 : 133 7.
41. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005 23 : 1803 10.
42. Saltz LB, Meropol NJ, Loehrer PJ Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004 22 : 1201 8.
43. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006 24 : 4914 21.
44. Lenz HJ, Meyer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. In : ASCO Annual Meeting 2004, Orlando; J Clin Oncol, 2004 ASCO Meeting Proceedings (Post-Meeting Ed.) 22 : 3510.
45. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007 25 : 1658 64.
46. Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005 23 : 9265 74.
47. Townsley CA, Major P, Siu LL, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006 94 : 1136 43.
48. Kuo T, Cho CD, Halsey J, et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005 23 : 5613 9.
49. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 351 : 337 45.
50. Van Cutsem E, Lang I, Nowacki M, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. In : ASCO Annual Meeting 2007, Chicago J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 : 4000.
51. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. In : ASCO Annual Meeting 2007, Chicago J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 : 4035.
52. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007 25 : 5225 32.
53. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006 8 (Suppl. 1 S7 14.
54. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006 55 : 657 70.
55. Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. In : 2007 Annual Meeting of the American Society of Clinical Oncology GI symposium, Orlando abstract 237; available at http://www.asco.org).
56. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized Phase II Trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007 25 : 4557 61.
57. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000 60 : 2178 89.
58. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) In : ASCO Annual Meeting, Orlando; J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Part I 23 : 3.
59. Koehne E, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). In : 2006 ASCO Annual Meeting, Atlanta J Clin Oncol, 2006 Annual Meeting Proceedings Part I 24 : 3508.
60. Kohne C, Banjetta E, Lin E, et al. Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. In : 2007 ASCO Annual Meeting, Chicago J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 : 4033.
61. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003 101 : 3597 605.
62. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004 240 : 644 57 discussion 657 8.
63. Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol 2005 23 : 9063 6.
64. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006 24 : 2065 72.
65. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. In : 2007 ASCO Annual Meeting, Chicago J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25 : LBA5.
66. Gibson TB, Grothey A. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression? Clin Colorectal Cancer 2006 6 : 196 201.
67. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006 24 : 394 400.
68. Petrioli R, Paolelli L, Marsili S, et al. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006 70 : 345 50.
69. Pasetto LM, D'Andrea MR, Jirillo A, Rossi E, Monfardini S. Stable disease in advanced colorectal cancer: therapeutic implications. Anticancer Res 2006 26 : 511 22.
70. Marshall J. Optimum use of biologics and role of maintenance therapy in colon cancer. Semin Oncol 2006 33 (6 Suppl. 11 S33 5.
71. Krol M, Koopman M, Uyl-de Groot C, Punt CJ. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin Pharmacother 2007 8 : 1313 28.
72. Jansman FG, Postma MJ, Brouwers JR. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 2007 25 : 537 62.
73. Starling N, Tilden D, White J, Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007 96 : 206 12.
74. Tappenden P, Jones R, Paisley S, Carroll C Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007 11 : 1 128, iii iv.
75. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007 12 : 38 50.